indomethacin has been researched along with Genetic Predisposition in 13 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Early postnatal steroids and indomethacin in combination have been shown to increase the risk of spontaneous intestinal perforation (SIP) in infants with extremely low birth weight (ELBW), but the mechanism behind this synergistic effect is unknown." | 7.74 | A neonatal mouse model of intestinal perforation: investigating the harmful synergism between glucocorticoids and indomethacin. ( Aschner, JL; Gaston, BM; Gordon, PV; Herman, AC; Laubach, VE; Marcinkiewicz, M, 2007) |
| "These findings indicate that young human subjects with a positive family history of hypertension have a defective vasodilator prostaglandin system, which is responsible for increased renal vascular sensitivity to angiotensin II." | 7.72 | Increased renal vascular sensitivity to angiotensin II in hypertension is due to decreased response to prostaglandins. ( Aurell, M; Herlitz, H; Palmgren, E; Widgren, B, 2003) |
| "To determine whether this effect is model specific, K-K system activation was investigated in a modified indomethacin induced enterocolitis model, as well as bradykinin 2 (B2) receptor distribution in the normal and acutely inflamed intestine." | 7.70 | Kallikrein-kininogen system activation and bradykinin (B2) receptors in indomethacin induced enterocolitis in genetically susceptible Lewis rats. ( Adam, AA; Blais, C; Colman, RW; Janardham, R; Sartor, RB; Stadnicka, I; Stadnicki, A, 1998) |
| "Continuous indomethacin (INDO) administration in the drinking water (10 to 20 microg/mL) profoundly inhibited plasmacytoma (PCT) development initiated by three 0." | 7.69 | Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain. ( Jones, GM; Potter, M; Wax, J, 1997) |
| "Early postnatal steroids and indomethacin in combination have been shown to increase the risk of spontaneous intestinal perforation (SIP) in infants with extremely low birth weight (ELBW), but the mechanism behind this synergistic effect is unknown." | 3.74 | A neonatal mouse model of intestinal perforation: investigating the harmful synergism between glucocorticoids and indomethacin. ( Aschner, JL; Gaston, BM; Gordon, PV; Herman, AC; Laubach, VE; Marcinkiewicz, M, 2007) |
| "These findings indicate that young human subjects with a positive family history of hypertension have a defective vasodilator prostaglandin system, which is responsible for increased renal vascular sensitivity to angiotensin II." | 3.72 | Increased renal vascular sensitivity to angiotensin II in hypertension is due to decreased response to prostaglandins. ( Aurell, M; Herlitz, H; Palmgren, E; Widgren, B, 2003) |
| "To evaluate whether the elevated blood pressure induced by chronic treatment with N(omega)-nitro-L-arginine methyl ester (L-NAME) contributes to an impairment of endothelium-dependent relaxation (EDR), the effects of chronic treatment of Wistar rats with L-NAME on systolic blood pressure, pulmonary arterial blood pressure and EDR of the pulmonary arteries were studied and compared with those of stroke-prone spontaneously hypertensive rats (SHRSP)." | 3.71 | Endothelium-dependent relaxation in pulmonary arteries of L-NAME-treated Wistar and stroke-prone spontaneously hypertensive rats. ( Kawata, K; Matsuda, K; Negishi, M; Sekiguchi, F; Shimamur, K; Shinomiya, K; Sunano, S; Yamamoto, K, 2002) |
| "To determine whether this effect is model specific, K-K system activation was investigated in a modified indomethacin induced enterocolitis model, as well as bradykinin 2 (B2) receptor distribution in the normal and acutely inflamed intestine." | 3.70 | Kallikrein-kininogen system activation and bradykinin (B2) receptors in indomethacin induced enterocolitis in genetically susceptible Lewis rats. ( Adam, AA; Blais, C; Colman, RW; Janardham, R; Sartor, RB; Stadnicka, I; Stadnicki, A, 1998) |
| "Continuous indomethacin (INDO) administration in the drinking water (10 to 20 microg/mL) profoundly inhibited plasmacytoma (PCT) development initiated by three 0." | 3.69 | Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain. ( Jones, GM; Potter, M; Wax, J, 1997) |
| "Indomethacin treatment (2 microg/g/d) for 7 days resulted in disruption of epithelial barrier integrity, but it caused neither a systemic inflammatory response nor a mucosal inflammatory response in the colon or cecum." | 1.34 | Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse. ( Churchill, TA; Dmytrash, AL; Doyle, J; Fedorak, RN; Macfarlane, SM; Sydora, BC; Walker, JW, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, TR | 1 |
| Shelton, EL | 1 |
| Van Driest, SL | 1 |
| Kannankeril, PJ | 1 |
| Reese, J | 1 |
| Steireif, C | 1 |
| García-Prieto, CF | 1 |
| Ruiz-Hurtado, G | 1 |
| Pulido-Olmo, H | 1 |
| Aranguez, I | 1 |
| Gil-Ortega, M | 1 |
| Somoza, B | 1 |
| Schönfelder, G | 1 |
| Schulz, A | 1 |
| Fernández-Alfonso, MS | 1 |
| Kreutz, R | 1 |
| Lu, W | 1 |
| Cheng, F | 1 |
| Jiang, J | 1 |
| Zhang, C | 1 |
| Deng, X | 1 |
| Xu, Z | 1 |
| Zou, S | 1 |
| Shen, X | 1 |
| Tang, Y | 1 |
| Huang, J | 1 |
| Gelfand, AA | 1 |
| Goadsby, PJ | 1 |
| Sekiguchi, F | 1 |
| Yamamoto, K | 1 |
| Matsuda, K | 1 |
| Kawata, K | 1 |
| Negishi, M | 1 |
| Shinomiya, K | 1 |
| Shimamur, K | 1 |
| Sunano, S | 1 |
| Palmgren, E | 1 |
| Widgren, B | 1 |
| Aurell, M | 1 |
| Herlitz, H | 1 |
| Zarza, J | 1 |
| Sydora, BC | 1 |
| Macfarlane, SM | 1 |
| Walker, JW | 1 |
| Dmytrash, AL | 1 |
| Churchill, TA | 1 |
| Doyle, J | 1 |
| Fedorak, RN | 1 |
| Gordon, PV | 1 |
| Herman, AC | 1 |
| Marcinkiewicz, M | 1 |
| Gaston, BM | 1 |
| Laubach, VE | 1 |
| Aschner, JL | 1 |
| Okumura, T | 1 |
| Shoji, E | 1 |
| Onodera, S | 1 |
| Kohgo, Y | 1 |
| Potter, M | 1 |
| Wax, J | 1 |
| Jones, GM | 1 |
| Stadnicki, A | 1 |
| Sartor, RB | 1 |
| Janardham, R | 1 |
| Stadnicka, I | 1 |
| Adam, AA | 1 |
| Blais, C | 1 |
| Colman, RW | 1 |
| Walker, UA | 1 |
| Venhoff, N | 1 |
1 review available for indomethacin and Genetic Predisposition
| Article | Year |
|---|---|
Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.
Topics: Acetaminophen; Animals; Disease Models, Animal; Ductus Arteriosus, Patent; Genetic Predisposition to | 2018 |
12 other studies available for indomethacin and Genetic Predisposition
| Article | Year |
|---|---|
Dissecting the genetic predisposition to albuminuria and endothelial dysfunction in a genetic rat model.
Topics: Acetylcholine; Albuminuria; Animals; Aorta; Arginine; Endothelium, Vascular; Genetic Predisposition | 2013 |
FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Genetic Predisposit | 2015 |
Primary sex headache in adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Combined Modality Therapy; Diagnosi | 2012 |
Endothelium-dependent relaxation in pulmonary arteries of L-NAME-treated Wistar and stroke-prone spontaneously hypertensive rats.
Topics: Animals; Arginine; Blood Pressure; Body Weight; Cardiovascular Agents; Endothelium, Vascular; Enzyme | 2002 |
Increased renal vascular sensitivity to angiotensin II in hypertension is due to decreased response to prostaglandins.
Topics: Adult; Angiotensin II; Blood Pressure; Body Mass Index; Cardiovascular Agents; Diastole; Dose-Respon | 2003 |
Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9.
Topics: Acenocoumarol; Aged; Aryl Hydrocarbon Hydroxylases; Benzodiazepines; Cytochrome P-450 CYP2C9; Drug I | 2003 |
Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse.
Topics: Animals; Bacteroides; Epithelium; Genetic Predisposition to Disease; Indomethacin; Inflammatory Bowe | 2007 |
A neonatal mouse model of intestinal perforation: investigating the harmful synergism between glucocorticoids and indomethacin.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Dexamethasone | 2007 |
Susceptibility to the development of gastric mucosal damage in OLETF rat not expressing the CCK-A receptor.
Topics: Animals; Ethanol; Gastric Mucosa; Genetic Predisposition to Disease; Hydrochloric Acid; Indomethacin | 1996 |
Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogens; Drug Antagonism | 1997 |
Kallikrein-kininogen system activation and bradykinin (B2) receptors in indomethacin induced enterocolitis in genetically susceptible Lewis rats.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Enterocolitis; Fem | 1998 |
Multiple mitochondrial DNA deletions and lactic acidosis in an HIV-infected patient under antiretroviral therapy.
Topics: Acidosis, Lactic; Anti-HIV Agents; Cell Line; DNA, Mitochondrial; Drug Therapy, Combination; Enzyme | 2001 |